ClinicalTrials.gg
CompletedNCT04136366Updated Jul 9, 2025Results posted

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

A Phase 3 interventional study of ADX-2191 (intravitreal methotrexate 0.8%) and Standard surgical care procedure in Proliferative Vitreoretinopathy, sponsored by Aldeyra Therapeutics, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Vitreoretinopathy, Proliferative with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Vitreoretinopathy, Proliferative · United States.

Enrollment
4th of 12
106 · median 69
Started
2019
with 1 other
Phase 3
Only one
of the 12
Registered
7th of 12
by date
Lead sponsor
1 of 12
Aldeyra Therapeutics, Inc.

Among the 12 studies in Vitreoretinopathy, Proliferative with a site in United States, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 3, and was the 7th registered.

Vitreoretinopathy, Proliferative

43 studies on the registry are indexed under Vitreoretinopathy, Proliferative; 11 are open to participants now.

Browse Vitreoretinopathy, Proliferative studies →

Open to participants now

2 of the 12 studies in Vitreoretinopathy, Proliferative with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Vitreoretinopathy, Proliferative studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Vitreoretinopathy, Proliferative with a site in United States, or all of them as a file.
02

Study summary

The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of proliferative vitreoretinopathy.

03

Conditions studied

  • Proliferative Vitreoretinopathy

Keywords

  • ADX-2191
  • recurrent retinal detachment
  • open globe injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 18 years or older of any gender or race
  2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to proliferative vitreoretinopathy or open globe injury
  3. Subject is willing and able to provide written , comply with clinical trial procedures, and return for all clinical trial visits
  4. Subjects of must agree to use two forms of for the duration of the clinical trial

Exclusion criteria

Exclusion Criteria:

  1. History of severe non-proliferative or proliferative diabetic retinopathy
  2. Other planned eye surgery during the course of the trial
  3. Participation in a clinical trial with an medicinal product or investigational device within 90 days of subject enrollment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    ADX-2191 (intravitreal methotrexate 0.8%)

    ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.

    Drug: ADX-2191 (intravitreal methotrexate 0.8%)

  • Active comparator
    Standard surgical care procedure

    Standard procedure performed.

    Other: Standard surgical care procedure

Interventions

  • ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy

  • OtherStandard surgical care procedure

    Standard surgical care performed upon completion of pars plana vitrectomy

06

What researchers measure

Primary outcomes

  1. Recurrent Retinal Detachment Compared to Historical Rates

    Percentage of subjects with recurrent retinal detachments requiring reoperation compared to historical rates

    Time frame: Efficacy assessment period (Week 1 to Week 24)

Secondary outcomes

  1. Number of Subjects With Recurrent Retinal Detachment

    Number of subjects with recurrent retinal detachment due to proliferative vitreoretinopathy

    Time frame: Efficacy assessment period (Week 1 to Week 24)

  2. Best-corrected Visual Acuity

    Change from baseline of best-corrected visual acuity using an early treatment diabetic retinopathy study (ETDRS) chart. The ETDRS chart contains seventy letters and the visual acuity letter score is equal to the total number of letters read correctly (0 = worst outcome, 70 = best outcome).

    Time frame: Efficacy assessment period (Week 1 to Week 24)

  3. Macular Epiretinal Membrane

    Number of subjects with macular epiretinal membrane assessed by spectral domain optical coherence tomography for study eye

    Time frame: Week 24

  4. Intraocular Pressure Less Than 5 mmHg for Study Eye

    Number of subjects with intraocular pressure less than 5 mmHg for study eye

    Time frame: Week 24

  5. Central Macular Subfield Thickness

    Number of subjects with central macular subfield thickness assessed by spectral domain optical coherence tomography for study eye

    Time frame: Week 24

07

Results

Posted Jul 9, 2025

Participant flow

Participant flow — Overall Study
MilestoneADX-2191Standard Surgical Care
Started6838
Completed5232
Not completed166

Outcome measures

PrimaryRecurrent Retinal Detachment Compared to Historical Rates

Percentage of subjects with recurrent retinal detachments requiring reoperation compared to historical rates

Time frame:
Efficacy assessment period (Week 1 to Week 24)
Reported as:
Number · percentage of subjects
Recurrent Retinal Detachment Compared to Historical Rates
percentage of subjectsADX-2191Standard Surgical Care
Recurrent Retinal Detachment Compared to Historical Rates18.820.6
SecondaryNumber of Subjects With Recurrent Retinal Detachment

Number of subjects with recurrent retinal detachment due to proliferative vitreoretinopathy

Time frame:
Efficacy assessment period (Week 1 to Week 24)
Reported as:
Count of participants · Participants
Number of Subjects With Recurrent Retinal Detachment
ParticipantsADX-2191Standard Surgical Care
Number of Subjects With Recurrent Retinal Detachment127
SecondaryBest-corrected Visual Acuity

Change from baseline of best-corrected visual acuity using an early treatment diabetic retinopathy study (ETDRS) chart. The ETDRS chart contains seventy letters and the visual acuity letter score is equal to the total number of letters read correctly (0 = worst outcome, 70 = best outcome).

Time frame:
Efficacy assessment period (Week 1 to Week 24)
Reported as:
Mean · correct letters
Best-corrected Visual Acuity
correct lettersADX-2191Standard Surgical Care
Best-corrected Visual Acuity16.9 ± 23.222.5 ± 27.4
SecondaryMacular Epiretinal Membrane

Number of subjects with macular epiretinal membrane assessed by spectral domain optical coherence tomography for study eye

Time frame:
Week 24
Reported as:
Count of participants · Participants
Macular Epiretinal Membrane
ParticipantsADX-2191Standard Surgical Care
Macular Epiretinal Membrane1812
SecondaryIntraocular Pressure Less Than 5 mmHg for Study Eye

Number of subjects with intraocular pressure less than 5 mmHg for study eye

Time frame:
Week 24
Reported as:
Count of participants · Participants
Intraocular Pressure Less Than 5 mmHg for Study Eye
ParticipantsADX-2191Standard Surgical Care
Intraocular Pressure Less Than 5 mmHg for Study Eye24
SecondaryCentral Macular Subfield Thickness

Number of subjects with central macular subfield thickness assessed by spectral domain optical coherence tomography for study eye

Time frame:
Week 24
Reported as:
Mean · microns
Central Macular Subfield Thickness
micronsADX-2191Standard Surgical Care
Central Macular Subfield Thickness384.4 ± 185.24473.7 ± 228.95

Adverse events

Collected over The safety assessment period was up to twenty-four weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-21910/68 (0%)0/68 (0%)39/68 (57.4%)
Standard Surgical Care0/38 (0%)1/38 (2.6%)24/38 (63.2%)
Most frequent serious events
Most frequent serious events
EventADX-2191Standard Surgical Care
DizzinessNervous system disorders0/681/38
Most frequent other events
Showing 10 of 30
Most frequent other events
EventADX-2191Standard Surgical Care
Eye painEye disorders9/689/38
Intraocular pressure increasedInvestigations2/688/38
Punctate keratitisEye disorders11/681/38
Macular fibrosisEye disorders4/686/38
Cystoid macular oedemaEye disorders5/685/38
Post procedural inflammationInjury, poisoning and procedural complications1/685/38
Corneal oedemaEye disorders4/684/38
Corneal epithelium defectEye disorders2/684/38
Anterior chamber cellEye disorders1/684/38
KeratitisEye disorders6/682/38

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)ADX-2191Standard Surgical CareTotal
<=18 years000
Between 18 and 65 years502373
>=65 years181533
Sex: Female, Male
Sex: Female, Male(Participants)ADX-2191Standard Surgical CareTotal
Female512475
Male171431
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADX-2191Standard Surgical CareTotal
Hispanic or Latino7310
Not Hispanic or Latino603595
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADX-2191Standard Surgical CareTotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American538
White583290
More than one race000
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(participants)ADX-2191Standard Surgical CareTotal
United States6838106
08

Study locations

23 sites
  • Retinal Consultants of Arizona
    Phoenix, Arizona 85053, United States
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • Florida Retina Institute
    Orlando, Florida 32806, United States
  • Bascom Palmer Eye Institute
    Palm Beach Gardens, Florida 33418, United States
  • Emory Eye Center
    Atlanta, Georgia 30322, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Illinois Retina Associates
    Joliet, Illinois 60435, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02214, United States
  • New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Kresge Eye Institute
    Detroit, Michigan 48201, United States
  • Associated Retinal Consultants
    Royal Oak, Michigan 48073, United States
  • Vitreo-Retinal Surgery
    Minneapolis, Minnesota 55432, United States
  • Mayo Clinic Ophthalmology
    Rochester, Minnesota 55905, United States
  • The Retina Institute
    St Louis, Missouri 63128, United States
  • Long Island VitreoRetinal Consultants
    Forest Hills, New York 11375, United States
  • Duke Health Center
    Durham, North Carolina 27705, United States
  • OHSU Casey Eye Institute
    Portland, Oregon 97239, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • University of Washington
    Seattle, Washington 98104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Jun 2022, 30 months.

Results were first posted in Jul 2025, 3 years after primary completion. A results delay was requested in May 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 23, 2019
StartActual
Nov 15, 2019
Primary completionActual
Jun 14, 2022
CompletionActual
Jun 14, 2022
Results delay requested
May 31, 2023
Results first posted
Jul 9, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04136366
Responsible party
Sponsor
First posted
Oct 23, 2019
Start date
Nov 15, 2019
Primary completion
Jun 14, 2022
Completion
Jun 14, 2022
Results posted
Jul 9, 2025
Last update
Jul 9, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion